Trump revokes planned Medicare/Medicaid coverage for GLP1s
Trump administration revokes the planned Medicare Part D coverage for anti-obesity GLP1 drugs.
Last year, the Biden administration's proposal to include GLP1s under Medicare part D was welcomed and lauded in the media:
Biden-Harris administration keen on GLP1s
The outgoing Biden-Harris admin puts out a proposal on widening access to GLP1s, which we hope the incoming Trump admin will also adopt.
GLP1.Guide Staff
🍃
Don't know what a GLP1 Receptor Agonist is, or how drugs like Ozempic, Mounjaro, Wegovy, or Zepbound work?
Check out our quick explainer
Check out our quick explainer
This year, it looks like the Trump administration has scrapped that proposal and will no longer pursue coverage for GLP1s:
CMS won’t cover GLP-1 drugs for weight loss in Medicare, Medicaid
The Trump administration last week dropped a Biden-era proposal that would have expanded coverage of GLP-1 drugs in Medicare and Medicaid programs, saying that it was “not appropriate at this time.” Here’s what you need to know.
As reported by HFMA, rather than outright rejecting the proposal, the Trump administration decided not to approve the proposal:
Final 2026 rule for MA, Part D leaves out proposed GLP-1 drug coverage
The Trump administration’s final rule setting policy and technical changes for Medicare Advantage (MA) in 2026 did not carry forward a proposal regarding GLP-1 drug coverage, but key provider-focused provisions were retained. The rule, which is scheduled for formal publication April 15 and also sets 2026 Medicare Part D policies, excludes a Biden administration proposal…
Nick Hut
Want to read the rest of our analysis on why the Trump administration might be pursuing this? The rest of this article is no longer available for free – if you'd like to read the rest of our analysis, check us out on Substack:
